(ta-floo-prost) ,


(trade name)


Therapeutic: ocular hypotensive agent
Pharmacologic: prostaglandins
Pregnancy Category: C


Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.


Acts as a prostaglandin analogues that decreases intraocular pressure by ↑ uveoscleral outflow.

Therapeutic effects

↓ intraocular pressure.


Absorption: Absorbed through cornea and is converted to the active metabolite tafluprost acid.
Distribution: Unknown.
Metabolism and Excretion: Further metabolized and eliminated.
Half-life: Unknown.

Time/action profile (↓ in intraocular pressure)

Ophthwithin 2–4 hr12 hr24 hr


Contraindicated in: Pediatric: Avoid use in children due to unknown safety of chronic ↑ pigmentation.
Use Cautiously in: Aphakia, pseudoaphakia with a torn posterior lens capsule; Known risk factors for macular edema; Obstetric: Women with child-bearing potential should practice adequate contraception; Lactation: Use cautiously in nursing women.

Adverse Reactions/Side Effects

Ear, Eye, Nose, Throat

  • conjunctival hyperemia (most frequent)
  • blurred vision
  • cataract
  • permanent iris pigmentation
  • eyelid pigmentation
  • lash pigmentation/increased thickness/↑ number
  • macular edema
  • ocular stinging/irritation


Drug-Drug interaction

Note noted.


Ophthalmic (Adults) One drop once daily (into conjunctival sac) in the evening into affected eye(s).


Ophthalmic solution : 0.0015% in 0.3 mL single-use containers

Nursing implications

Nursing assessment

  • Measure intraocular pressure periodically during therapy.

Potential Nursing Diagnoses

Readiness for enhanced knowledge, related to medication regimen (Patient/Family Teaching)


  • Ophthalmic: Wash hands prior to instillation. Pull lower lid downward and look up. Instill 1 drop in conjunctival sac each evening. Each unit is for one-time use; discard after using. Store unopened foil pouches in refrigerator. Do not open pouch until ready to use.
    • If used with other ophthalmic medications, administer at least 5 min apart.

Patient/Family Teaching

  • Instruct patient to use drops as directed. Do not use more than 1 drop daily; may increase intraocular pressure. Do not use for a condition for which it was not prescribed. Do not share with others, even if they have the same symptoms; may cause harm.
  • Advise patient to read the Patient Information Leaflet prior to initiating therapy and with each Rx refill in case of changes.
  • Inform patient of potential side effects including brownish color of the iris; may be permanent. Also, darkening of the eyelid, increasing length, thickness, color, or number of eyelashes, and hair growth on eyelids; usually reversible.
  • Advise patient to notify health care professional if eye injury, eye infection, sudden loss of vision, eye surgery, swelling and redness around eye, or problems with eyelids occur.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient use adequate contraception during therapy and to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.

Evaluation/Desired Outcomes

  • Reduction of intraocular pressure.
References in periodicals archive ?
2mL BC Monopost Preservative free, DE Tafluprost Saflutan Lens changes, 15[micro]g/ml Preservative free, DE dry eyes, transient 30x0.
Tafluprost is a PGA with pharmacological properties similar to those of latanoprost and it is characterized by the absence of preservatives (FOGAGNOLO et al.
Of the four prostaglandin analogs, three have no human eye data, bimatoprost (Lumigan), tafluprost (Zioptan), and travoprost (Travatan Z).
SAFLUTAN is the proposed trade name for tafluprost in the US.
The new treatment, tafluprost, contains none of the detergents that give rise to adverse reactions and is far more "patient friendly" than its predecessors.
Professor Ian Grierson, head of ophthalmology at the University of Liverpool, said: "Given that compliance is a central issue for many people, tafluprost may help reduce rates of discontinuation as it may be a much more comfortable treatment for use in the long term.
The tafluprost glaucoma drops are the first of their kind that avoid unpleasant side effects which can put patients off, including burning, itching, tears, or a "dry eye" sensation.
The two ophthalmic preparations are ocriplasmin (jetrea; symptomatic vitreomacular adhesions) and tafluprost (Zioptan; glaucoma).
Supplies of timolol (Timoptol), dorzolamide (Trusopt) and dorzolamide with timolol (Cosopt) preservative-free products were affected but MSD's preservative-free prostaglandin analogue tafluprost (Saflutan) was not, owing to a different source of manufacture (Santen Pharmaceutical).
5% & Dorzolamide 2% lopidine Apraclonidine 1% Saflutan Tafluprost Table 2 Fixed-dose combination treatments currently available for glaucoma management Trade Name Generic Name Cosopt Timolol 0.